Being in my unique position, I have garnered over 15 years worth of structured pricing on various cardiology-centric equipment, supplies, and services. Want reassurance you're getting most out of your money? Click the 'Contact Us' button above or email me directly: email@example.com
For those that have your NCT or PET certification through the NMTCB, for a limited time, they are offering current active specialty certificants who can show acceptable documentation of 24 hours of specialty-specific CE credit by December 31, 2020 will have their specialty credential extended for another 7 years from the time of recertification.
Read more here on NMTCB website
Back in January of 2017 I posted a link to a JNM issue where Dr.Jeffry Siegel challenged the status quo on medical radiation: Renowned Medical Physicist Jeffry A. Siegel dispels the 70 year old hypothesis that exposure to medical radiation could increase ones risk of cancer. In fact, he suggests it more likely helps prevent it.
He emphasized, "This fear is unjustified by any scientific findings and is discredited by most experimental and epidemiological studies, which show that low-dose radiation, instead, stimulates protective responses provided by eons of evolution, resulting in beneficial effects."
Not only are these articles becoming more commonplace in the JNM, the JNC now has an article (August 2019, Volume 26, Issue 4, pp 1358–1360) titled: LNT RIP: It is time to bury the linear no threshold hypothesis. To what degree are these articles challenging the status-quo? Far enough to where Springer Nature mandates the authors mention the following: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Back in June of 2017, I highlighted a SNMMI article that caught my attention. The header read: Arterial CO2 as a Potent Coronary Vasodilator: A Preclinical PET/MR Validation Study with Implications for Cardiac Stress Testing Fast forward to today, and it appears Cedars is really investing the resources to confirm if carbon dioxide is a viable, cost-effective, safe alternative to A2A agonists like Adenosine/Regadenoson. They've even created an incubator program called the "Dharmakumar Laboratory."